🔴 Rocket Pharmaceuticals is trading 5% down today as immediate cause remains uncertain

Rocket Pharmaceuticals is trading 5.07% down at $3.18, with no clear company-specific catalyst identified for the September 23, 2026 decline.

• Recent coverage highlighted favorable FDA alignment for the RP-A501 Danon disease trial and a Needham upgrade to Buy; both were previously reported.
• Biotech is rising broadly, while major U.S. indexes are lower, leaving the immediate cause of the sharper move uncertain.